Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
21 september 2017 bijgewerkt door: AHS Cancer Control Alberta
Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have demonstrated significant anti-myeloma effects in preclinical lab and animal studies.
The goal of this phase I trial is to evaluate in patients with relapsed or refractory multiple myeloma the safety, toxicity profile and tolerability of ABT-888 (Veliparib) administered on a schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a dose-finding / dose escalation phase I trial of ABT-888 (Veliparib) in combination with Bortezomib and Dexamethasone in patients with relapsed or refractory multiple myeloma. ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle.
First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
19
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Confirmed diagnosis of multiple myeloma.
- Measurable disease, according to the International Myeloma Working Group criteria.
- ECOG performance status 0, 1 or 2.
- Patients must have received prior treatment for MM and have relapsed or progressed on prior therapy; no limit on number of prior treatment regimens, but prior treatment must be completed 2 weeks prior to registration. Prior exposure to Bortezomib is not an exclusion criteria as long as patients did not progress or relapse while receiving or within 3 months of completing trt with bortezomib
- Prior radiation, completed at least 4 weeks prior to registration, is permitted.
- Adequate marrow reserve, liver and renal function
Exclusion Criteria:
- patients with a history of other malignancies, except: adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, prostate cancer with stable PSA for > 3 years, or other solid tumours curatively treated with no evidence of disease for > 5 years.
- Patients with preexisting grade 2 (or higher) sensory neuropathy or grade 1 sensory neuropathy with neuropathic pain.
- Pregnant or lactating women
- Patients receiving concurrent treatment with other anti-cancer therapy any other investigational agents.
- Active or uncontrolled infections
- Patient with known documented congenital or acquired risk factor for thromboembolic event
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ABT-888/Bortezomib
Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
|
ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle.
First dose to be given within 1 hour of Bortezomib on day 1.
Planned starting dose is 20 mg PO every 12 hours.
Starting dose escalation is planned until an MTD is reached.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Determine the maximum tolerated dose (MTD) of ABT-888.
Tijdsspanne: 21 Day Cycle
|
Study follows a modified dose escalation scheme with a 3+3 design (3 to 6 patients per dose level or cohort).
Only the ABT-888 dose will be escalated with a maximum dose of ABT-888 of 100 mg PO BID.
If >1 out 6 patients at any dose level suffer dose limiting toxicity, then dose escalation is stopped, and this dose is declared as MTD. 3 additional patients will be entered at the next lowest dose level.
The recommended phase 2 dose is defined as the dose level with ≤ 1 out of 6 patients experiencing DLTs at the highest dose level below the MTD.
|
21 Day Cycle
|
|
Identify the Dose Limiting Toxicities (DLT) of ABT-888
Tijdsspanne: 21 Day Cycle
|
All adverse events, including DLTs, are graded according to the NCI CTCAE, v4.0.
A DLT is defined as any grade 3 or higher non-hematologic toxicity, or any grade 4 hematologic toxicity, considered by the investigator to be related to the study drugs and occurring during Days 1-22 of Cycle 1.
|
21 Day Cycle
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Activity Objective - Preliminary assessment of the anti-tumor activity of ABT-888
Tijdsspanne: 21 day cycle
|
Response to study drugs is assessed at the end of each cycle according to the International Myeloma Working Group (IMWG) response criteria.
|
21 day cycle
|
|
Exploratory Objective - Preliminary assessment of potential biomarkers
Tijdsspanne: 24 months
|
Gene expression profiling is performed at baseline and compared between responders versus non-responders in order to identify a "treatment response signature".
2.5 mg of RNA will be extracted from plasma cells sorted from pre-treatment (D1, cycle 1) (n=20) and post-treatment (D11, cycle 1) (n=20) bone marrow aspirates collected from patients treated in the extension cohort.
cRNAs will be hybridized onto the U133 Plus 2.0 gene chips and raw data files acquired using Affymetrix Microarray Suite version 5.1 software and analyzed with the Partek Genomics Suite v6.4.
|
24 months
|
|
Exploratory Objective - Determine in vivo the effect of ABT-888 on PARP inhibitors.
Tijdsspanne: 24 Months
|
Poly-ADP-ribose (PAR) levels are measured in sorted CD138+ plasma cells from pre-ABT-888 treatment on day 1 cycle1, as well as post ABT-888 treatment (within 4-6 hours) on days 4 and 11.
PAR levels will be measured by standardized ELISA assays (HT PARP in vivo Pharmacodynamic Assay II™, Trevigen).
|
24 Months
|
|
Determine invivo the effects of Bortezomib on the plasma cells DNA genes expression and function
Tijdsspanne: 24 Months
|
Gene expression profiling is performed at baseline prior to treatment with bortezomib and on days 4 and 11 post bortezomib treatment.
2.5 mg of RNA will be extracted from plasma cells sorted from bone marrow aspirates collected from patients treated on trial.
cRNAs will be hybridized onto the U133 Plus 2.0 gene chips and raw data files acquired using Affymetrix Microarray Suite version 5.1 software and analyzed with the Partek Genomics Suite v6.4.
|
24 Months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Studie stoel: Nizar J Bahlis, M.D., Tom Baker Cancer Centre, University of Calgary
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 oktober 2011
Primaire voltooiing (Werkelijk)
1 februari 2015
Studie voltooiing (Werkelijk)
10 februari 2015
Studieregistratiedata
Eerst ingediend
16 november 2011
Eerst ingediend dat voldeed aan de QC-criteria
16 december 2011
Eerst geplaatst (Schatting)
20 december 2011
Updates van studierecords
Laatste update geplaatst (Werkelijk)
25 september 2017
Laatste update ingediend die voldeed aan QC-criteria
21 september 2017
Laatst geverifieerd
1 september 2017
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hart-en vaatziekten
- Vaatziekten
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Hematologische ziekten
- Hemorragische aandoeningen
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Multipel myeloom
- Neoplasmata, plasmacel
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Poly (ADP-ribose) polymeraseremmers
- Bortezomib
- Veliparib
Andere studie-ID-nummers
- MM11-01
- E24055 (Andere identificatie: CHREB- University of Calgary)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .